The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Open accessAbstract
HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of four different T-cell clonotypes that specifically targeted KRAS G12D. However, one of these lesions had progressed on evaluation 9 months after therapy. The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I major histocompatibility complex (MHC) molecule. The loss of expression of this molecule provided a direct mechanism of tumor immune evasion. Thus, the infusion of CD8+ cells targeting mutant KRAS mediated effective antitumor immunotherapy against a cancer that expressed mutant KRAS G12D and HLA-C*08:02.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This approach has shown efficacy in colon cancer and NSCLC patients with mutant KRAS G12D and HLA-C*08:02 expression [88].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Tumors with mutant KRAS can express neoantigen fragments containing the oncogenic driver mutation on the major histocompatibility complex [88,89].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [88]
In the citing paper
“CD8+ TILs and TCRs in CD4+ T cells have been found to specifically recognize KRAS-related mutations, which can be further used to engineer T cells.604,605”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [604]
In the citing paper
“As noted above, peptides derived from KRASG12 variants193,194, and also from KRASQ61H/L/R (ref.198), have been demonstrated to be presented on the surface of malignant cells by various MHC I (HLA-A) molecules.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“ACT with these specific TILs resulted in regression of all seven pulmonary metastases in a patient with KRASG12D-mutant CRC from whom they had been isolated193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Notably, loss of MHC was identified as an immune-evasion mechanism in a tumour that progressed 9 months after TIL infusion193.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Endogenous immune responses against KRAS-mutant cancer cells were first described in 2016 by Tran et al.193, who identified CD8+ TILs with T cell receptors (TCRs) that recognize MHC I (HLA-C*08:02)-presented peptide neoepitopes derived from KRASG12D.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [193]
In the citing paper
“Using CD8+ T cells that were reactive to KRASG12D mutant, a patient with CRC experienced prolonged partial response [64].”
From KRAS, a New Target for Precision Medicine in Colorectal Cancer? (2024) · cites this paper as [64]
In the citing paper
“It was found that CD8+ T cells, possessing HLA-C08:02-restricted T-cell receptors, specifically recognize the mutant KRASG12D.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Following the intravenous administration of expanding TCRs in an ex vivo environment, a complete response was observed in lung lesions, resulting in prolonged PFS.”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“A recent publication presented the relationship between the KRASG12D mutation and TCRs in a patient diagnosed with metastatic mCRC with lung metastasis [106].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [106]
In the citing paper
“Despite the rarity of HLA-C*08:02, this study demonstrated the promise of T-cell–based immunotherapy for targeting KRASG12D and HLA-C*08:02.”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“Tran and colleagues described a case of a patient with metastatic colorectal cancer treated with autologous T cells specific for mutant KRASG12D, which was restricted to the major histocompatibility complex class I allele HLA-C*08:02 (44).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [44]
In the citing paper
“The anti-tumor activity of ICB has been shown to depend on CD8+ T cell, HLA class I–dependent immune activity (34–36).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
McGranahan, N., Furness, A. J. S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S. K., Jamal-Hanjani, M., Wilson, G. A., Birkbak, N. J., Hiley, C. T., et al. (2016) · Science · doi:10.1126/science.aaf1490 · Cited by 3,065
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208
Self-citationCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,737
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625
Self-citationAllele-specific copy number analysis of tumors
Loo, P. V., Nord, S., Lingjærde, O. C., Russnes, H. G., Rye, I. H., Sun, W., Weigman, V., Marynen, P., Zetterberg, A., Naume, B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009843107 · Cited by 1,192
Cited by
Sorted by citations
Items 501–600 of 1,002
The Role of T Cell Immunotherapy in Acute Myeloid Leukemia
Hao, F., Sholy, C., Wang, C., Cao, M., & Kang, X. (2021) · Cells · doi:10.3390/cells10123376 · Cited by 34
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
Omer, B. A., Cardenas, M. G., Pfeiffer, T., Daum, R. E., Huynh, M., Sharma, S., Nouraee, N., Xie, C., Tat, C. L., Perconti, S., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0307 · Cited by 34
Neoantigen-directed therapeutics in the clinic: where are we?
Lybaert, L., Thielemans, K., Feldman, S. A., van der Burg, S. H., Bogaert, C., & Ott, P. A. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.004 · Cited by 35
Sei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 36
Nanoparticle-Mediated Synergistic Chemoimmunotherapy for Cancer Treatment
Lang, X., Wang, X., Han, M., & Guo, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s455213 · Cited by 36
Evolving adoptive cellular therapies in urological malignancies
Wong, Y. N. S., Joshi, K., Pulè, M. A., Peggs, K. S., Swanton, C., Quezada, S. A., & Linch, M. D. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30327-3 · Cited by 33
Oba, T., Hoki, T., Yamauchi, T., Keler, T., Marsh, H. C., Cao, X., & Ito, F. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000347 · Cited by 33
Immune Checkpoint Inhibitors in the Treatment of Cancer
Zam, W., & Ali, L. (2021) · Current Clinical Pharmacology · doi:10.2174/1574884716666210325095022 · Cited by 33
Li, Z., Chen, G., Cai, Z., Dong, X., He, L., Qiu, L., Zeng, Y., Liu, X., & Liu, J. (2020) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2021.03.08 · Cited by 34
Targeting KRAS in Non-Small Cell Lung Cancer
de la Fuente, E. C., Olmedo, M. E., Rueda, A. G., Lage, Y., & Garrido, P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.792635 · Cited by 34
Andrews, M. C., Reuben, A., Gopalakrishnan, V., & Wargo, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00946 · Cited by 33
Drugging the Undruggable Ras — Immunotherapy to the Rescue?
June, C. H. (2016) · New England Journal of Medicine · doi:10.1056/nejme1612215 · Cited by 33
Leveraging mRNA technology for antigen based immuno-oncology therapies
Floudas, C. S., Sarkizova, S., Ceccarelli, M., & Zheng, W. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010569 · Cited by 32
Zhou, J., Zhao, W., Wu, J., Lu, J., Ding, Y., Wu, S., Wang, H., Ding, D., Mo, F., Zhou, Z. M., et al. (2019) · BioMed Research International · doi:10.1155/2019/8103142 · Cited by 32
Immunogenicity and Immune Silence in Human Cancer
Yarmarkovich, M., Farrel, A., Sison, A., di Marco, M., Raman, P., Parris, J. L. D., Monos, D. S., Lee, H., Stevanović, S., & Maris, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00069 · Cited by 32
Keshinro, A. O., Vanderbilt, C., Kim, J. K., Fırat, C., Chen, C., Yaeger, R. D., Ganesh, K., Segal, N. H., Gönen, M., Shia, J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00456 · Cited by 32
Mullinax, J. E., Egger, M. E., McCarter, M. D., Monk, B. J., Toloza, E. M., Brousseau, S., Jagasia, M., & Sarnaik, A. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000608 · Cited by 32
Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review
Bteich, F., Mohammadi, M., Li, T., Bhat, M. A., Sofianidi, A. A., Wei, N., & Kuang, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512030 · Cited by 34
Specht, G., Roetschke, H. P., Mansurkhodzhaev, A., Henklein, P., Textoris‐Taube, K., Urlaub, H., Mishto, M., & Liepe, J. (2020) · Scientific Data · doi:10.1038/s41597-020-0487-6 · Cited by 32
Penter, L., Dietze, K., Ritter, J. M., Cobo, M. F. L., Garmshausen, J., Aigner, F., Bullinger, L., Hackstein, H., Wienzek‐Lischka, S., Blankenstein, T. J. F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1586409 · Cited by 31
Facing the future: challenges and opportunities in adoptive T cell therapy in cancer
Magalhaes, I., Carvalho‐Queiroz, C., Hartana, C. A., Kaiser, A. M., Lukic, A., Mints, M., Nilsson, O., Grönlund, H., Mattsson, J., & Berglund, S. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1608179 · Cited by 31
Robertson, J. D., Salm, M., & Dangl, M. (2019) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2019.09.003 · Cited by 31
Wickström, S. L., Lövgren, T., Volkmar, M., Reinhold, B. B., Duke‐Cohan, J. S., Hartmann, L., Rebmann, J., Müeller, A., Melief, J., Maas, R. R., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02766 · Cited by 32
The Ways of Isolating Neoantigen-Specific T Cells
Li, Q., & Ding, Z. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01347 · Cited by 31
Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved
Fritsch, E. F., Burkhardt, U. E., Hacohen, N., & Wu, C. J. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0526 · Cited by 31
The evolving landscape of immunotherapy in solid tumors
Keilson, J. M., Knochelmann, H. M., Paulos, C. M., Kudchadkar, R. R., & Lowe, M. (2021) · Journal of Surgical Oncology · doi:10.1002/jso.26416 · Cited by 31
Pyke, R. M., Mellacheruvu, D., Dea, S., Abbott, C. W., McDaniel, L., Bhave, D. P., Zhang, S. V., Levy, É., Bartha, G. T., West, J. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29203-w · Cited by 32
TSNAdb v2.0: The Updated Version of Tumor-Specific Neoantigen Database
Wu, J., Chen, W., Zhou, Y., Chi, Y., Hua, X., Wu, J., Gu, X., Chen, S., & Zhou, Z. M. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.09.012 · Cited by 32
van den Bulk, J., van der Ploeg, M., Ijsselsteijn, M. E., Ruano, D., van der Breggen, R., Duhen, R., Peeters, K. C. M. J., Sarasqueta, A. F., Verdegaal, E. M. E., van der Burg, S. H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005887 · Cited by 32
Jiang, T., Su, C., Cheng, R., Pan, Y., Zhang, H., He, J., He, Y., Tang, R., Ren, S., & Zhou, C. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.03 · Cited by 33
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Immune vulnerabilities of mutant KRAS in pancreatic cancer
Cheng, N. C., & Vonderheide, R. H. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.07.004 · Cited by 32
Mog, B. J., Marcou, N., DiNapoli, S. R., Pearlman, A. H., Nichakawade, T. D., Hwang, M. S., Douglass, J., Hsiue, E. H.-C., Glavaris, S. A., Wright, K. M., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adg7123 · Cited by 31
Rath, J. A., Bajwa, G., Carrères, B. M., Hoyer, E. A., Gruber, I., Martinez-Paniagua, M. A., Yu, Y.-R., Nouraee, N., Sadeghi, F., Wu, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz7809 · Cited by 30
Maine, C. J., Richard, G., Spasova, D. S., Miyake-Stoner, S. J., Sparks, J., Moise, L., Sullivan, R. P., Garijo, O., Choz, M., Crouse, J. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.11.027 · Cited by 30
Olsson, N., Heberling, M. L., Zhang, L., Jhunjhunwala, S., Phung, Q. T., Lin, S., Anania, V. G., Lill, J. R., & Elias, J. E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662443 · Cited by 30
Gorzo, A., Galoș, D., Volovăț, S. R., Lungulescu, C. V., Burz, C. C., & Sur, D. G. (2022) · Life · doi:10.3390/life12020229 · Cited by 30
Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer
Zhu, Y., Zhou, J., Zhu, L., Hu, W., Liu, B., & Xie, L. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2060019 · Cited by 30
Chatani, P. D., Lowery, F. J., Parikh, N. B., Hitscherich, K. J., Yossef, R., Hill, V. K., Gartner, J. J., Paria, B. C., Florentin, M., Ray, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006264 · Cited by 30
Self-citationLynn, G. M., Laga, R., & Jewell, C. M. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.114427 · Cited by 31
Seliger, B., & Ferrone, S. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9773-2_15 · Cited by 30
Mariuzza, R. A., Wu, D., & Pierce, B. G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303304 · Cited by 30
Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy
Shao, W., Yao, Y., Yang, L., Li, X., Ge, T., Zheng, Y., Zhu, Q., Ge, S., Gu, X., Jia, R., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00504-8 · Cited by 30
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR
Leung, W. K., & Heslop, H. E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0888 · Cited by 30
Lee, M. S., & Pant, S. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321255 · Cited by 30
Itoh, T., Kawai, Y., Yasui, Y., Iriguchi, S., Minagawa, A., Ishii, T., Miyoshi, H., Taketo, M. M., Kawada, K., Obama, K., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02195-x · Cited by 30
Kishton, R. J., Vodnala, S. K., Vizcardo, R., & Restifo, N. P. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.10.001 · Cited by 29
Neoantigens and their potential applications in tumor immunotherapy (Review)
Fang, X., Guo, Z., Liang, J., Wen, J., Liu, Y., Guan, X., & Hong, L. (2022) · Oncology Letters · doi:10.3892/ol.2022.13208 · Cited by 29
Liu, K., Geng, Y., Wang, L., Xu, H., Zou, M., Li, Y., Zhao, Z., Chen, T., Xu, F., Sun, L. D., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13279 · Cited by 29
Targeting KRAS in Pancreatic Cancer
Cowzer, D., Zameer, M., Conroy, M. R., Kölch, W., & Duffy, A. G. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111870 · Cited by 34
Adoptive cell transfer immunotherapy for patients with solid epithelial cancers
Rosenberg, S. A., Parkhurst, M. R., & Robbins, P. F. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.003 · Cited by 29
Self-citationCoengineering specificity, safety, and function into T cells for cancer immunotherapy
Attianese, G. M. P. G., Ash, S., & Irving, M. B. (2023) · Immunological Reviews · doi:10.1111/imr.13252 · Cited by 29
Klein, S., Mauch, C., Wagener‐Ryczek, S., Schoemmel, M., Buettner, R., Quaas, A., & Helbig, D. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02339-3 · Cited by 30
Therapeutic Targets of KRAS in Colorectal Cancer
Rahman, S., Garrel, S., Gerber, M., Maitra, R., & Goel, S. (2021) · Cancers · doi:10.3390/cancers13246233 · Cited by 28
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Bryant, G., Wang, L., & Mulholland, D. J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071542 · Cited by 30
Advances in Chimeric Antigen Receptor T‐Cell Therapies for Solid Tumors
Baybutt, T. R., Flickinger, J. C., Caparosa, E. M., & Snook, A. E. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1280 · Cited by 28
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.006 · Cited by 30
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies
Jones, H. F., Molvi, Z., Klatt, M. G., Dao, T., & Scheinberg, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585385 · Cited by 28
TSNAD v2.0: A one-stop software solution for tumor-specific neoantigen detection
Zhou, Z. M., Wu, J., Ren, J.-N., Chen, W., Zhao, W., Gu, X., Chi, Y., He, Q., Yang, B., Wu, J., et al. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.08.016 · Cited by 28
Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
Alausa, A. O., Lawal, K. A., Babatunde, O. A., Obiwulu, E. N. O., Oladokun, O. C., Fadahunsi, O. S., Celestine, U. O., Moses, E. U., Akaniro, I. R., & Adegbola, P. I. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106264 · Cited by 29
Immunotherapies against HER2-Positive Breast Cancer
Duro‐Sánchez, S., Alonso, M. R., & Arribas, J. (2023) · Cancers · doi:10.3390/cancers15041069 · Cited by 29
Candidate immune biomarkers for radioimmunotherapy
Lévy, A., Nigro, G., Sansonetti, P. J., & Deutsch, É. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.02.006 · Cited by 28
Eisenberg, G., Engelstein, R., Geiger-Maor, A., Hajaj, E., Merims, S., Frankenburg, S., Uzana, R., Rutenberg, A., Machlenkin, A., Frei, G. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0383 · Cited by 28
Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties
Hickey, J. W., Isser, A., Vicente, F. P., Warner, S. B., Mao, H., & Schneck, J. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.029 · Cited by 28
Forghieri, F., Riva, G., Lagreca, I., Barozzi, P., Vallerini, D., Morselli, M., Paolini, A., Bresciani, P., Colaci, E., Maccaferri, M., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26617 · Cited by 28
Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations
Iiizumi, S., Ohtake, J., Murakami, N., Kouro, T., Kawahara, M., Isoda, F., Hamana, H., Kishi, H., Nakamura, N., & Sasada, T. (2019) · Cancers · doi:10.3390/cancers11020266 · Cited by 30
A Spontaneous Aggressive ERα+ Mammary Tumor Model Is Driven by Kras Activation
Campbell, K. M., O’Leary, K. A., Rugowski, D. E., Mulligan, W. A., Barnell, E. K., Skidmore, Z. L., Krysiak, K., Griffith, M., Schuler, L. A., & Griffith, O. L. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.098 · Cited by 28
Wu, D., Yin, R., Chen, G., Ribeiro-Filho, H. V., Cheung, M., Robbins, P. F., Mariuzza, R. A., & Pierce, B. G. (2024) · Science Advances · doi:10.1126/sciadv.adq6150 · Cited by 27
Self-citationmRNA cancer vaccines from bench to bedside: a new era in cancer immunotherapy
Shariati, A., Khani, P., Nasri, F., Afkhami, H., Khezrpour, A., Kamrani, S., Shariati, F. S., Alavimanesh, S., & Modarressi, M. H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00692-9 · Cited by 27
Chae, Y. K., Oh, M. S., & Giles, F. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0354 · Cited by 28
Bai, P., Li, Y., Zhou, Q., Xia, J., Wei, P., Deng, H., Wu, M., Chan, S. K., Kappler, J. W., Zhou, Y., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1868130 · Cited by 27
Self-citationAdoptive Cellular Therapy for Solid Tumors
Bear, A. S., Fraietta, J. A., Narayan, V., O’Hara, M. H., & Haas, N. B. (2021) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_321115 · Cited by 31
GOF Mutant p53 in Cancers: A Therapeutic Challenge
Dolma, L., & Muller, P. A. J. (2022) · Cancers · doi:10.3390/cancers14205091 · Cited by 29
Neoantigen-specific TCR-T cell-based immunotherapy for acute myeloid leukemia
Zhou, W., Yu, J., Li, Y., & Wang, K. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00353-3 · Cited by 27
Generation of colon cancer–derived tumor-infiltrating T cells (TILs) for adoptive cell therapy
Albrecht, H. C., Gustavus, D., Schwanemann, J., Dammermann, W., Lippek, F., Weylandt, K. H., Hoffmeister, H., & Gretschel, S. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.01.009 · Cited by 27
T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer
Eisenberg, V., Hoogi, S., Shamul, A., Barliya, T., & Cohen, C. J. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.007 · Cited by 27
Moghaddam, S. J., Savai, R., Salehi‐Rad, R., Sengupta, S., Kammer, M. N., Massion, P. P., Beane, J., Ostrin, E. J., Priolo, C., Tennis, M. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1168st · Cited by 26
Tian, L., Li, H., Cui, H., Tang, C., Zhao, P., Wang, X., & Cheng, Y. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08101-1 · Cited by 26
Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells
Paria, B. C., Levin, N., Lowery, F. J., Pasetto, A., Deniger, D. C., Parkhurst, M. R., Yossef, R., Kim, S. P., Florentin, M., Ngo, L. T., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000342 · Cited by 26
Self-citationWei, P., Jordan, K. R., Buhrman, J. D., Lei, J., Deng, H., Marrack, P., Dai, S., Kappler, J. W., Slansky, J. E., & Yin, L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100588118 · Cited by 26
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 26
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Fenton, G. A., & Mitchell, D. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2257 · Cited by 26
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy
Martinov, T., & Greenberg, P. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-082114 · Cited by 27
Advances in immunotyping of colorectal cancer
Wu, Y., Jing, Z., Qu, Z., Yang, X., & Han, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1259461 · Cited by 27
Mechanisms of Resistance in Multiple Myeloma
Papadas, A., & Asimakopoulos, F. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_10 · Cited by 26
From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
Saliani, M., Jalal, R., & Ahmadian, M. R. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0530 · Cited by 27
Li, Q., Zeng, H., Liu, T., Wang, P., Zhang, R., Zhao, B., Feng, T., Yang, Y., Wu, J., Zheng, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54650-y · Cited by 25
Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial
Huff, A. L., Haldar, S. D., Girgis, A. A., Wang, H. H., Danilova, L., Heumann, T. R., Berg, M., Wang, Y., Andaloori, L., Hernandez, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68324-4 · Cited by 26
Gene editing enables T-cell engineering to redirect antigen specificity for potent tumor rejection
Albers, J. J., Ammon, T., Gosmann, D., Audehm, S., Thoene, S., Winter, C., Secci, R., Wolf, A. A., Stelzl, A., Steiger, K., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900367 · Cited by 25
Tan, Q., Zhang, C., Yang, W., Liu, Y., Palashati, H., Feng, D., Xing, L., Yang, K., & Lu, Z. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0709-7 · Cited by 25
Zhang, Y., Lin, Z., Wan, Y., Cai, H., Deng, L., & Li, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02472 · Cited by 25
Hino, C., Pham, B., Park, D., Yang, C., Nguyen, M. H. K., Kaur, S., Reeves, M. E., Xu, Y., Nishino, K., Pu, L., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061410 · Cited by 26
Current Landscape of Immunotherapy for Advanced Sarcoma
Albarrán, V., Villamayor, M. L., Pozas, J., Chamorro, J., Rosero, D. I., Román, M. S., Guerrero, P., de Aguado, P. P., Calvo, J. C., de Quevedo, C. G., et al. (2023) · Cancers · doi:10.3390/cancers15082287 · Cited by 25
Bradley, S. D., Talukder, A. H., Lai, I. P., Davis, R. K., Alvarez, H., Tiriac, H., Zhang, M., Chiu, Y., Melendez, B., Jackson, K. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19141-w · Cited by 29
Biomaterial-based scaffolds for direct in situ programming of tumor-infiltrating T lymphocytes
Inamdar, V. V., Hao, S., Stephan, S. B., & Stephan, M. T. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.040 · Cited by 24
Li, Z., Ma, L., Gao, Z., Wang, X., Che, X., Zhang, P., Li, Y., Zhang, Q., Liu, T., Sun, Y., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03749-8 · Cited by 24
Zhao, K.-Y., Du, Y., Cao, H., Su, L., Su, X., & Li, X. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114435 · Cited by 25
Shared neoantigens for cancer immunotherapy
Goloudina, A. R., Chevalier, F. L., Authié, P., Charneau, P., & Majlessi, L. (2025) · Molecular Therapy Oncology · doi:10.1016/j.omton.2025.200978 · Cited by 26
Tumour-infiltrating lymphocyte therapy landscape: prospects and challenges
Chen, R., Johnson, J. E., Roudkoli, A. R., & Dudek, A. Z. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2024-000566 · Cited by 29
Metadata
- Authors
- Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., Kriley, I. R., & Rosenberg, S. A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-12-08
- Volume
- 375
- Issue
- 23
- Pages
- 2255-2262
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5178827
- OpenAlex
- W2559953355
- Cited by
- 1,368
- References
- 27
- Citations by year
- 2026: 96 · 2025: 132 · 2024: 129 · 2023: 162 · 2022: 162 · 2021: 183 · 2020: 149 · 2019: 134 · 2018: 118 · 2017: 98 · 2016: 3
- FWCI
- 71.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (Z01BC010984)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- tumor-infiltrating lymphocytes, mutant KRAS, KRAS G12D, CD8+ T cells, tumor immune evasion, MHC class I loss, cancer immunotherapy
- MeSH terms
- Female, Flow Cytometry, Humans, Lung, Lung Neoplasms, Middle Aged, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), CD8-Positive T-Lymphocytes, Lymphocyte Count
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
